ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014
Rationale for eliminating Staphylococcus breakpoints for β-lactam agents other than penicillin, oxacillin or cefoxitin, and ceftaroline.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Phenotypic resistance to life-saving antimicrobials in Gram-positive bacteria isolated from wild birds in Northern Italy: a One Health surveillance perspective.One health (Amsterdam, Netherlands) · 2026Article
- Cefazolin Versus Antistaphylococcal Penicillins in Methicillin-SusceptibleAntibiotics (Basel, Switzerland) · 2026Review
- Evaluating veterinaryJournal of clinical microbiology · 2026Article
- CoNS blood culture isolates from very preterm infants: antibiotic susceptibility, synergy testing andJAC-antimicrobial resistance · 2026Article
- Re-examining cephalosporin activity against methicillin-susceptibleJAC-antimicrobial resistance · 2026Article
- Veterinary method evaluation of Vitek-2 compact for antimicrobial susceptibility testing ofJournal of clinical microbiology · 2026Article
- Using BONCAT to dissect the proteome ofmSphere · 2025Article
- Optimizing cefazolin dosing for central nervous system infections: insights from population pharmacokinetics and Monte Carlo simulations.Antimicrobial agents and chemotherapy · 2025Article
- Restoring susceptibility to β-lactam antibiotics in methicillin-resistant Staphylococcus aureus.Nature chemical biology · 2025Article
- Changes in the epidemiology of neonatal bacteremia during the COVID-19 pandemic in Wuhan, China.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Synergistic potential of LeuBMC microbiology · 2024Article
- Coverage gaps in empiric antibiotic regimens used to treat serious bacterial infections in neonates and children in Southeast Asia and the Pacific.The Lancet regional health. Southeast Asia · 2024Article
- The Neonatal and Paediatric Pharmacokinetics of Antimicrobials study (NAPPA): investigating amoxicillin, benzylpenicillin, flucloxacillin and piperacillin pharmacokinetics from birth to adolescence.The Journal of antimicrobial chemotherapy · 2023Article
- Disc Test for Detecting Staphylococcus aureus Strains Producing Type A and Type C β-Lactamases.Microbiology spectrum · 2023Article
- Impact of Bicarbonate on PBP2a Production, Maturation, and Functionality in Methicillin-ResistantAntimicrobial agents and chemotherapy · 2023Article
- Prevalence and Potential Risk Factors for the Acquisition of Antibiotic-ResistantBioMed research international · 2023Article
- Cefadroxil Comparable to Cephalexin: Minimum Inhibitory Concentrations among Methicillin-Susceptible Staphylococcus aureus Isolates from Pediatric Musculoskeletal Infections.Microbiology spectrum · 2022Article
- The NaHCOAntimicrobial agents and chemotherapy · 2022Article
- Impacts of NaHCOAntibiotics (Basel, Switzerland) · 2022Article
- Evaluation of in-house cefoxitin screening broth to determine methicillin-resistant staphylococci.Heliyon · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Due to the ongoing concern about the reliability of Staphylococcus breakpoints (interpretive criteria) for other β-lactam agents, the Clinical and Laboratory Standards Institute recently approved the elimination of all breakpoints for antistaphylococcal β-lactams except for penicillin, oxacillin or cefoxitin, and ceftaroline. Routine testing of penicillin and oxacillin or cefoxitin should be used to infer susceptibility for all β-lactams with approved clinical indications for staphylococcal infections. It is critical for laboratories to reject requests for susceptibility testing of other β-lactams against staphylococci and to indicate that susceptibility to these agents can be predicted from the penicillin and oxacillin or cefoxitin results. This article reviews β-lactam resistance mechanisms in staphylococci, current antimicrobial susceptibility testing and reporting recommendations for β-lactams and staphylococci, and microbiologic data and clinical data supporting the elimination of staphylococcal breakpoints for other β-lactam agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.